Loading…
Urocortin 2 in cardiovascular health and disease
•Urocortin (Ucn)-2 regulates cardiac function.•Ucn-2/CRH-R2 system activation promotes a consistent relaxation of the vessels.•Animal studies have shown beneficial therapeutic effects of Ucn-2 in heart failure.•Therapeutic benefits of Ucn-2 have also been shown in patients with heart failure.•Ucn-2...
Saved in:
| Published in: | Drug discovery today 2015-07, Vol.20 (7), p.906-914 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c459t-10d2fb47c2e54111b0f54e4b3594a28dcc8d86de5f616eda92b5860fb8b269b53 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c459t-10d2fb47c2e54111b0f54e4b3594a28dcc8d86de5f616eda92b5860fb8b269b53 |
| container_end_page | 914 |
| container_issue | 7 |
| container_start_page | 906 |
| container_title | Drug discovery today |
| container_volume | 20 |
| creator | Adão, Rui Santos-Ribeiro, Diana Rademaker, Miriam T. Leite-Moreira, Adelino F. Brás-Silva, Carmen |
| description | •Urocortin (Ucn)-2 regulates cardiac function.•Ucn-2/CRH-R2 system activation promotes a consistent relaxation of the vessels.•Animal studies have shown beneficial therapeutic effects of Ucn-2 in heart failure.•Therapeutic benefits of Ucn-2 have also been shown in patients with heart failure.•Ucn-2 is emerging as a promising therapeutic option for cardiovascular diseases.
Urocortin (Ucn)-2 – corticotropin-releasing hormone receptor 2 signaling has favorable effects in the cardiovascular system, including coronary vasodilatation, with increased coronary blood flow and conductance and augmented cardiac contractility and output, as well as protection against ischemia/reperfusion injury. Indeed, several animal studies have confirmed the salutary therapeutic effects of Ucn-2 in chronic heart failure, with improvements in cardiac performance and animal survival. In addition, recent clinical trials have demonstrated the benefits of Ucn-2 in patients with stable chronic heart failure on optimal medical therapy. |
| doi_str_mv | 10.1016/j.drudis.2015.02.012 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1695760819</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1359644615000975</els_id><sourcerecordid>1695760819</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-10d2fb47c2e54111b0f54e4b3594a28dcc8d86de5f616eda92b5860fb8b269b53</originalsourceid><addsrcrecordid>eNp9kD1PwzAURS0EoqXwDxDKyJJgO7bjLEio4kuqxEJnyx8vqqs0KXZSiX-PqxRGluc3nOtrH4RuCS4IJuJhW7gwOh8LigkvMC0woWdoTmQlcy5Lep72kte5YEzM0FWMW5yImotLNKO8YhJLOUd4HXrbh8F3Gc3SsDo43x90tGOrQ7YB3Q6bTHcuS1WgI1yji0a3EW5O5wKtX54_l2_56uP1ffm0yi3j9ZAT7GhjWGUpcEYIMbjhDJhJL2KaSmetdFI44I0gApyuqeFS4MZIQ0VteLlA99O9-9B_jRAHtfPRQtvqDvoxKiJqXgksSZ1QNqE29DEGaNQ--J0O34pgdXSltmpypY6uFKYqmUixu1PDaHbg_kK_chLwOAGQ_nnwEFS0HjoLzgewg3K9_7_hB1n_e3Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1695760819</pqid></control><display><type>article</type><title>Urocortin 2 in cardiovascular health and disease</title><source>ScienceDirect Freedom Collection</source><creator>Adão, Rui ; Santos-Ribeiro, Diana ; Rademaker, Miriam T. ; Leite-Moreira, Adelino F. ; Brás-Silva, Carmen</creator><creatorcontrib>Adão, Rui ; Santos-Ribeiro, Diana ; Rademaker, Miriam T. ; Leite-Moreira, Adelino F. ; Brás-Silva, Carmen</creatorcontrib><description>•Urocortin (Ucn)-2 regulates cardiac function.•Ucn-2/CRH-R2 system activation promotes a consistent relaxation of the vessels.•Animal studies have shown beneficial therapeutic effects of Ucn-2 in heart failure.•Therapeutic benefits of Ucn-2 have also been shown in patients with heart failure.•Ucn-2 is emerging as a promising therapeutic option for cardiovascular diseases.
Urocortin (Ucn)-2 – corticotropin-releasing hormone receptor 2 signaling has favorable effects in the cardiovascular system, including coronary vasodilatation, with increased coronary blood flow and conductance and augmented cardiac contractility and output, as well as protection against ischemia/reperfusion injury. Indeed, several animal studies have confirmed the salutary therapeutic effects of Ucn-2 in chronic heart failure, with improvements in cardiac performance and animal survival. In addition, recent clinical trials have demonstrated the benefits of Ucn-2 in patients with stable chronic heart failure on optimal medical therapy.</description><identifier>ISSN: 1359-6446</identifier><identifier>EISSN: 1878-5832</identifier><identifier>DOI: 10.1016/j.drudis.2015.02.012</identifier><identifier>PMID: 25748088</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Cardiovascular Agents - chemistry ; Cardiovascular Agents - therapeutic use ; Cardiovascular System - drug effects ; Cardiovascular System - metabolism ; Cardiovascular System - physiopathology ; Chronic Disease ; Heart Failure - drug therapy ; Heart Failure - metabolism ; Heart Failure - physiopathology ; Humans ; Protein Conformation ; Receptors, Corticotropin-Releasing Hormone - agonists ; Receptors, Corticotropin-Releasing Hormone - metabolism ; Signal Transduction - drug effects ; Structure-Activity Relationship ; Urocortins - chemistry ; Urocortins - metabolism ; Urocortins - therapeutic use</subject><ispartof>Drug discovery today, 2015-07, Vol.20 (7), p.906-914</ispartof><rights>2015 Elsevier Ltd</rights><rights>Copyright © 2015 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-10d2fb47c2e54111b0f54e4b3594a28dcc8d86de5f616eda92b5860fb8b269b53</citedby><cites>FETCH-LOGICAL-c459t-10d2fb47c2e54111b0f54e4b3594a28dcc8d86de5f616eda92b5860fb8b269b53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25748088$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Adão, Rui</creatorcontrib><creatorcontrib>Santos-Ribeiro, Diana</creatorcontrib><creatorcontrib>Rademaker, Miriam T.</creatorcontrib><creatorcontrib>Leite-Moreira, Adelino F.</creatorcontrib><creatorcontrib>Brás-Silva, Carmen</creatorcontrib><title>Urocortin 2 in cardiovascular health and disease</title><title>Drug discovery today</title><addtitle>Drug Discov Today</addtitle><description>•Urocortin (Ucn)-2 regulates cardiac function.•Ucn-2/CRH-R2 system activation promotes a consistent relaxation of the vessels.•Animal studies have shown beneficial therapeutic effects of Ucn-2 in heart failure.•Therapeutic benefits of Ucn-2 have also been shown in patients with heart failure.•Ucn-2 is emerging as a promising therapeutic option for cardiovascular diseases.
Urocortin (Ucn)-2 – corticotropin-releasing hormone receptor 2 signaling has favorable effects in the cardiovascular system, including coronary vasodilatation, with increased coronary blood flow and conductance and augmented cardiac contractility and output, as well as protection against ischemia/reperfusion injury. Indeed, several animal studies have confirmed the salutary therapeutic effects of Ucn-2 in chronic heart failure, with improvements in cardiac performance and animal survival. In addition, recent clinical trials have demonstrated the benefits of Ucn-2 in patients with stable chronic heart failure on optimal medical therapy.</description><subject>Animals</subject><subject>Cardiovascular Agents - chemistry</subject><subject>Cardiovascular Agents - therapeutic use</subject><subject>Cardiovascular System - drug effects</subject><subject>Cardiovascular System - metabolism</subject><subject>Cardiovascular System - physiopathology</subject><subject>Chronic Disease</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - metabolism</subject><subject>Heart Failure - physiopathology</subject><subject>Humans</subject><subject>Protein Conformation</subject><subject>Receptors, Corticotropin-Releasing Hormone - agonists</subject><subject>Receptors, Corticotropin-Releasing Hormone - metabolism</subject><subject>Signal Transduction - drug effects</subject><subject>Structure-Activity Relationship</subject><subject>Urocortins - chemistry</subject><subject>Urocortins - metabolism</subject><subject>Urocortins - therapeutic use</subject><issn>1359-6446</issn><issn>1878-5832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp9kD1PwzAURS0EoqXwDxDKyJJgO7bjLEio4kuqxEJnyx8vqqs0KXZSiX-PqxRGluc3nOtrH4RuCS4IJuJhW7gwOh8LigkvMC0woWdoTmQlcy5Lep72kte5YEzM0FWMW5yImotLNKO8YhJLOUd4HXrbh8F3Gc3SsDo43x90tGOrQ7YB3Q6bTHcuS1WgI1yji0a3EW5O5wKtX54_l2_56uP1ffm0yi3j9ZAT7GhjWGUpcEYIMbjhDJhJL2KaSmetdFI44I0gApyuqeFS4MZIQ0VteLlA99O9-9B_jRAHtfPRQtvqDvoxKiJqXgksSZ1QNqE29DEGaNQ--J0O34pgdXSltmpypY6uFKYqmUixu1PDaHbg_kK_chLwOAGQ_nnwEFS0HjoLzgewg3K9_7_hB1n_e3Y</recordid><startdate>20150701</startdate><enddate>20150701</enddate><creator>Adão, Rui</creator><creator>Santos-Ribeiro, Diana</creator><creator>Rademaker, Miriam T.</creator><creator>Leite-Moreira, Adelino F.</creator><creator>Brás-Silva, Carmen</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150701</creationdate><title>Urocortin 2 in cardiovascular health and disease</title><author>Adão, Rui ; Santos-Ribeiro, Diana ; Rademaker, Miriam T. ; Leite-Moreira, Adelino F. ; Brás-Silva, Carmen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-10d2fb47c2e54111b0f54e4b3594a28dcc8d86de5f616eda92b5860fb8b269b53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Cardiovascular Agents - chemistry</topic><topic>Cardiovascular Agents - therapeutic use</topic><topic>Cardiovascular System - drug effects</topic><topic>Cardiovascular System - metabolism</topic><topic>Cardiovascular System - physiopathology</topic><topic>Chronic Disease</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - metabolism</topic><topic>Heart Failure - physiopathology</topic><topic>Humans</topic><topic>Protein Conformation</topic><topic>Receptors, Corticotropin-Releasing Hormone - agonists</topic><topic>Receptors, Corticotropin-Releasing Hormone - metabolism</topic><topic>Signal Transduction - drug effects</topic><topic>Structure-Activity Relationship</topic><topic>Urocortins - chemistry</topic><topic>Urocortins - metabolism</topic><topic>Urocortins - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Adão, Rui</creatorcontrib><creatorcontrib>Santos-Ribeiro, Diana</creatorcontrib><creatorcontrib>Rademaker, Miriam T.</creatorcontrib><creatorcontrib>Leite-Moreira, Adelino F.</creatorcontrib><creatorcontrib>Brás-Silva, Carmen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drug discovery today</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adão, Rui</au><au>Santos-Ribeiro, Diana</au><au>Rademaker, Miriam T.</au><au>Leite-Moreira, Adelino F.</au><au>Brás-Silva, Carmen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Urocortin 2 in cardiovascular health and disease</atitle><jtitle>Drug discovery today</jtitle><addtitle>Drug Discov Today</addtitle><date>2015-07-01</date><risdate>2015</risdate><volume>20</volume><issue>7</issue><spage>906</spage><epage>914</epage><pages>906-914</pages><issn>1359-6446</issn><eissn>1878-5832</eissn><abstract>•Urocortin (Ucn)-2 regulates cardiac function.•Ucn-2/CRH-R2 system activation promotes a consistent relaxation of the vessels.•Animal studies have shown beneficial therapeutic effects of Ucn-2 in heart failure.•Therapeutic benefits of Ucn-2 have also been shown in patients with heart failure.•Ucn-2 is emerging as a promising therapeutic option for cardiovascular diseases.
Urocortin (Ucn)-2 – corticotropin-releasing hormone receptor 2 signaling has favorable effects in the cardiovascular system, including coronary vasodilatation, with increased coronary blood flow and conductance and augmented cardiac contractility and output, as well as protection against ischemia/reperfusion injury. Indeed, several animal studies have confirmed the salutary therapeutic effects of Ucn-2 in chronic heart failure, with improvements in cardiac performance and animal survival. In addition, recent clinical trials have demonstrated the benefits of Ucn-2 in patients with stable chronic heart failure on optimal medical therapy.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>25748088</pmid><doi>10.1016/j.drudis.2015.02.012</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-6446 |
| ispartof | Drug discovery today, 2015-07, Vol.20 (7), p.906-914 |
| issn | 1359-6446 1878-5832 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1695760819 |
| source | ScienceDirect Freedom Collection |
| subjects | Animals Cardiovascular Agents - chemistry Cardiovascular Agents - therapeutic use Cardiovascular System - drug effects Cardiovascular System - metabolism Cardiovascular System - physiopathology Chronic Disease Heart Failure - drug therapy Heart Failure - metabolism Heart Failure - physiopathology Humans Protein Conformation Receptors, Corticotropin-Releasing Hormone - agonists Receptors, Corticotropin-Releasing Hormone - metabolism Signal Transduction - drug effects Structure-Activity Relationship Urocortins - chemistry Urocortins - metabolism Urocortins - therapeutic use |
| title | Urocortin 2 in cardiovascular health and disease |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T12%3A47%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Urocortin%202%20in%20cardiovascular%20health%20and%20disease&rft.jtitle=Drug%20discovery%20today&rft.au=Ad%C3%A3o,%20Rui&rft.date=2015-07-01&rft.volume=20&rft.issue=7&rft.spage=906&rft.epage=914&rft.pages=906-914&rft.issn=1359-6446&rft.eissn=1878-5832&rft_id=info:doi/10.1016/j.drudis.2015.02.012&rft_dat=%3Cproquest_cross%3E1695760819%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c459t-10d2fb47c2e54111b0f54e4b3594a28dcc8d86de5f616eda92b5860fb8b269b53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1695760819&rft_id=info:pmid/25748088&rfr_iscdi=true |